Dyslipidemia

Metabolic·MeSH: Dyslipidemias

18 drugs in development·11 companies·5 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
fenofibrate	ANI PHARMACEUTICALS INC (ANIP)
TriCor™	ABBOTT LABORATORIES (ABT)

Phase 3(4)

Drug	Company
monotherapy ezetimibe	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
monotherapy obicetrapib	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib + ezetimibe	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib + ezetimibe fdc	NEWAMSTERDAM PHARMA CO N.V. (NAMS)

Phase 2(2)

Drug	Company
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg q 2 weeks	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
sln312	Silence Therapeutics Plc (SLN)

Phase 1(5)

Drug	Company
aln-apoc3	REGENERON PHARMACEUTICALS, INC. (REGN)
ARO-ANG3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-APOC3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ly3885125	ELI LILLY & Co (LLY)
obicetrapib	NEWAMSTERDAM PHARMA CO N.V. (NAMS)

Preclinical(2)

Drug	Company
cdx-101	CARDAX, INC. (CDXI)
DGAT-1 inhibitors	Viking Therapeutics, Inc. (VKTX)

Unknown(2)

Drug	Company
gemcabene	MetaVia Inc. (MTVA)
Lipanthyl™	ABBOTT LABORATORIES (ABT)

Phase 4(1)

Drug	Company
yangxin dawayimixike honey paste	NYMOX PHARMACEUTICAL CORP (NYMXF)

BioSniper tracks 18 drugs in development for Dyslipidemia across 11 companies.

There are 5 clinical trials targeting Dyslipidemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.